Immunotherapy with ligands of natural killer T cells

Trends in Molecular Medicine

Volumn 8, Issue 5, 2002, Pages 225-231

  Wilson, Michael T ^a   Singh, Avneesh K ^a   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL FUNCTION; CELL STIMULATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; REVIEW; TUMOR; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD1; CELL DIFFERENTIATION; CYTOKINES; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; MICE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHENOTYPE;

EID: 0036256943     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02325-0     Document Type: Review

References (65)

1. The instructive role of innate immunity in the acquired immune response
2. Mouse CD1-specific NK1 T cells: Development, specificity, and function
3. NKT cells: Facts, functions and fallacies
4. CD1d and natural T cells: How their properties jump-start the immune system
5. Autoreactivity by design: Innate B and T lymphocytes
6. Functional diversity of helper T lymphocytes
7. Lipid antigen presentation in the immune system: Lessons learned from CD1d knockout mice
8. + Vα14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major
9. During Trypanosoma cruzi infection CD1d-restricted NKT cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein
10. CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi
11. Monocyte chemoattractant protein-1-dependent increase of Vα14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection
12. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus
13. + T cells and amplification of anti-viral immune responses to respiratory syncytial virus
14. Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls
15. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice
16. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis
17. Critical contribution of liver natural killer T cells to a murine model of hepatitis
18. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis
19. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction
20. Differential tumor surveillance by natural killer (NK) and NKT cells
21. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
22. Immune suppression and skin cancer development: Regulation by NKT cells
23. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
24. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
25. NKT cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen
26. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse
27. CD1-restricted NKT cells protect nonobese diabetic mice from developing diabetes
28. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
29. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance
30. Agelasphins, novel α-galactosylceramides from the marine sponge Agelas mauritianus
31. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
32. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
33. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells
34. Activation of NKT cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
35. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
36. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
37. Immunization with α-galactosylceramide polarizes CD1-reactive NKT cells towards Th2 cytokine synthesis
38. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 naturalkiller T cells
39. + natural killer T cells by α-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis
40. α-galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria
41. Natural killer T cell activation inhibits hepatitis B virus replication in vivo
42. Inhibition of hepatitis B virus replication by activated NKT cells does not require inflammatory cell recruitment to the liver
43. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
44. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide
45. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes
46. Redirecting Th1 and Th2 responses in autoimmune disease
47. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
48. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoiminune Type 1 diabetes
49. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets
50. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis
51. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis
52. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells
53. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice
54. KRN7000, an NKT cell enhancer, in patients with solid tumors - A phase I study of the EORTC BTDG
55. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide
56. Involvement ofdecidual Vα14 NKT cells in abortion
57. The natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines
58. Enhancing effects of (2S,3S,4R)-1-O-(α-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3, 4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells
59. Treatment of hepatic metastasis of the Colon26 adenocarcinoma with an α-galactosylceramide, KRN7000
60. Antitumor activity of α-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production
61. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
62. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
63. Antitumor effect of α-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver
64. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by αgalactosylceramide in mice
65. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide